- Home
- LGCL vs NVNO Comparison
LGCL vs NVNO Comparison
Compare LGCL & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- NVNO
- Stock Information
- Founded
- LGCL 2009
- NVNO 1987
- Country
- LGCL China
- NVNO United States
- Employees
- LGCL N/A
- NVNO N/A
- Industry
- LGCL
- NVNO Medical/Dental Instruments
- Sector
- LGCL
- NVNO Health Care
- Exchange
- LGCL NYSE
- NVNO Nasdaq
- Market Cap
- LGCL 39.7M
- NVNO 41.0M
- IPO Year
- LGCL 2024
- NVNO N/A
- Fundamental
- Price
- LGCL $0.55
- NVNO $3.52
- Analyst Decision
- LGCL
- NVNO
- Analyst Count
- LGCL 0
- NVNO 0
- Target Price
- LGCL N/A
- NVNO N/A
- AVG Volume (30 Days)
- LGCL 73.9K
- NVNO 72.6K
- Earning Date
- LGCL 01-01-0001
- NVNO 07-30-2025
- Dividend Yield
- LGCL N/A
- NVNO N/A
- EPS Growth
- LGCL N/A
- NVNO N/A
- EPS
- LGCL 0.07
- NVNO N/A
- Revenue
- LGCL $145,690,427.00
- NVNO N/A
- Revenue This Year
- LGCL N/A
- NVNO N/A
- Revenue Next Year
- LGCL N/A
- NVNO $409.09
- P/E Ratio
- LGCL $8.03
- NVNO N/A
- Revenue Growth
- LGCL N/A
- NVNO N/A
- 52 Week Low
- LGCL $0.28
- NVNO $2.03
- 52 Week High
- LGCL $3.31
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- NVNO 54.88
- Support Level
- LGCL N/A
- NVNO $3.44
- Resistance Level
- LGCL N/A
- NVNO $3.81
- Average True Range (ATR)
- LGCL 0.00
- NVNO 0.25
- MACD
- LGCL 0.00
- NVNO -0.04
- Stochastic Oscillator
- LGCL 0.00
- NVNO 47.05
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.